Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New obesity drug HM15275 enters Mid-Stage trial

NCT ID NCT07205900

Disease control Sponsor: Hanmi Pharmaceutical Company Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests an experimental drug called HM15275 for weight loss in 267 adults who are obese or overweight but do not have diabetes. Participants receive either the drug or a placebo as a weekly injection for 36 weeks. The main goal is to see how much body weight changes from the start to the end of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HM15275 (injectable drug)
What this could lead to
If successful, this could lead to a new weight-loss medication for people with obesity or overweight.
What could go wrong
This is an early phase 2 trial with only 267 people, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

267 people

The number who actually took part.

Started

Dec 2025

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria 1. Participant's age at the time of signing the informed consent: * United States: 18 to 75 years (inclusive) * Korea: 19 to 75 years (inclusive) 2. BMI ≥30 kg/m² and ≤50 kg/m², or ≥27 kg/m² and \<30 kg/m² with ≥1 weight-related comorbidity 3. Body weight change \<5% over the past 3 months prior to screening 4. Capable of giving signed informed consent, ability and willingness to comply with all protocol procedures Key Exclusion Criteria: 1. Type 1 diabetes mellitus or T2DM, or HbA1c ≥6.5% / FPG ≥126 mg/dL 2. Obesity due to endocrine/genetic disorders 3. Planned or prior obesity surgery (unless \>1 year ago for liposuction/abdominoplasty), or device-based obesity therapy (unless removed \>6 months ago) 4. Personal history or current diagnosis of acute or chronic pancreatitis or factors that may increase the risk of pancreatitis, such as a history of cholelithiasis (without cholecystectomy) or alcohol abuse. 5. Personal or family history of medullary thyroid carcinoma (MTC) or a known genetic condition (e.g., multiple endocrine neoplasia type 2) that predisposes the participant to MTC. 6. Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening. 7. History or current diagnosis of congestive heart failure (NYHA class Ⅲ or Ⅳ), or myocardial infarction, stroke, unstable angina, transient ischemic attack, or revascularization procedure (e.g., stent or bypass graft surgery) within 3 months prior to screening visit 8. Personal history or current diagnosis of acute or chronic pancreatitis or factors that may increase the risk of pancreatitis, such as a history of cholelithiasis (without cholecystectomy) or alcohol abuse.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESE Obesity

Contacts and locations

Locations

  • Accellacare of Bristol-PAC of Tennessee

    Bristol, Tennessee, 37620, United States

  • Accellacare of Cary - Cary Medical Group

    Cary, North Carolina, 27511, United States

  • Accellacare of Charleston

    Mt. Pleasant, South Carolina, 29464, United States

  • Accellacare of Duly - Duly Oak Lawn

    Oak Lawn, Illinois, 60453, United States

  • Accellacare of Hickory

    Hickory, North Carolina, 28601, United States

  • Accellacare of McFarland

    Ames, Iowa, 50010, United States

  • Accellacare of Piedmont - Piedmont HealthCare

    Statesville, North Carolina, 28626, United States

  • Accellacare of Wilmington, LLC

    Wilmington, North Carolina, 28401, United States

  • Accellacare of Winston Salem

    Winston-Salem, North Carolina, 27103, United States

  • Bristol-Internal Medicine and Pediatric Associates of Bristol, P.C.

    Bristol, Tennessee, 37620, United States

  • ProSciento Inc

    Chula Vista, California, 91911, United States

  • Raleigh Medical Group, P.A.

    Raleigh, North Carolina, 27609, United States

  • Texas Clinical Research Institute

    Arlington, Texas, 76012, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.